risankizumab-话题@MedSci

#risankizumab#

6篇内容 | 1919人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2264400, encodeId=1f54226440003, content=<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a> <a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a> <a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=NEJM：Risankizumab与Ustekinumab治疗中重度克罗恩病疗效和安全性对比, objectType=article, longId=875438, objectId=d51a8e5438a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240704/1720065244146_92910.jpg, objectUrl=/article/show_article.do?id=d51a8e5438a6, replyNumber=0, likeNumber=14, createdTime=2025-05-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d51a8e5438a6, moduleTitle=NEJM：Risankizumab与Ustekinumab治疗中重度克罗恩病疗效和安全性对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d51a8e5438a6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2217907, encodeId=69ed221e90788, content=<a href='/topic/show?id=2e6e6e0315d' target=_blank style='color:#2F92EE;'>#炎症性肠病#</a> <a href='/topic/show?id=e913135e4a2' target=_blank style='color:#2F92EE;'>#ozanimod#</a> <a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a> <a href='/topic/show?id=4a291193275' target=_blank style='color:#2F92EE;'>#Mirikizumab#</a> <a href='/topic/show?id=b4dc11e41036' target=_blank style='color:#2F92EE;'>#Brazikumab#</a>, objectTitle=J Gastroenterol：炎症性肠病治疗新篇章——S1P调节剂与IL-23抑制剂, objectType=article, longId=836771, objectId=6039836e711a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240729/cb12cbdafb2e4c21adbe465f75c3e4c5-eSvfLOOWQihN.jpg, objectUrl=/article/show_article.do?id=6039836e711a, replyNumber=0, likeNumber=95, createdTime=2024-08-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=6039836e711a, moduleTitle=J Gastroenterol：炎症性肠病治疗新篇章——S1P调节剂与IL-23抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6039836e711a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189242, encodeId=f59f2189242b0, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a> <a href='/topic/show?id=2178651e5ec' target=_blank style='color:#2F92EE;'>#活动性溃疡性结肠炎#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024：Risankizumab在中度至重度活动性溃疡性结肠炎患者中的疗效和安全性, objectType=article, longId=814628, objectId=7995814628eb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240224/1708780755122_8624274.png, objectUrl=/article/show_article.do?id=7995814628eb, replyNumber=0, likeNumber=92, createdTime=2024-02-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7995814628eb, moduleTitle=ECCO 2024：Risankizumab在中度至重度活动性溃疡性结肠炎患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7995814628eb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183366, encodeId=58482183366fb, content=<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a> <a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=IBD：Risankizumab治疗中至重度多重难治性克罗恩病患者的真实世界有效性和安全性, objectType=article, longId=810560, objectId=0af78105603e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/abdominal-pain-s2a-photo-of-pain-area-and-internal-abdominal-organs.jpg, objectUrl=/article/show_article.do?id=0af78105603e, replyNumber=0, likeNumber=119, createdTime=2024-01-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0af78105603e, moduleTitle=IBD：Risankizumab治疗中至重度多重难治性克罗恩病患者的真实世界有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af78105603e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1014424, encodeId=92fa101442462, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=Lancet：risankizumab对中重度斑块状银屑病的疗效和安全性, objectType=article, longId=146414, objectId=e01b14641415, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201808/20180811162446993.jpg, objectUrl=/article/show_article.do?id=e01b14641415, replyNumber=0, likeNumber=121, createdTime=2021-09-03, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01b14641415, moduleTitle=Lancet：risankizumab对中重度斑块状银屑病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e01b14641415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1014423, encodeId=ceff10144232c, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=ICER：Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处, objectType=article, longId=145944, objectId=6e0014594413, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201808/20180805122909128.jpeg, objectUrl=/article/show_article.do?id=6e0014594413, replyNumber=0, likeNumber=111, createdTime=2021-09-03, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e0014594413, moduleTitle=ICER：Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e0014594413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201903/20190301233851398.jpg, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=128, createdTime=2021-09-03, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1014420, encodeId=5cc71014420ae, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, objectType=article, longId=175399, objectId=02b91e539906, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201907/20190713190807884.jpg, objectUrl=/article/show_article.do?id=02b91e539906, replyNumber=0, likeNumber=135, createdTime=2021-09-03, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b91e539906, moduleTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02b91e539906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1014419, encodeId=d61c10144194a, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=Lancet：Risankizumab治疗中重度银屑病患者的疗效优于阿达木单抗, objectType=article, longId=177806, objectId=ebab1e78068a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201908/20190816185749561.jpg, objectUrl=/article/show_article.do?id=ebab1e78068a, replyNumber=0, likeNumber=132, createdTime=2021-09-03, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebab1e78068a, moduleTitle=Lancet：Risankizumab治疗中重度银屑病患者的疗效优于阿达木单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebab1e78068a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1014418, encodeId=0bf81014418f1, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a><a href='/topic/show?id=d4d196630b4' target=_blank style='color:#2F92EE;'>#银屑病#</a>, objectTitle=JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响, objectType=article, longId=216683, objectId=469921668328, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202193/1630679605910_2269929.png, objectUrl=/article/show_article.do?id=469921668328, replyNumber=0, likeNumber=208, createdTime=2021-09-03, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=469921668328, moduleTitle=JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=469921668328)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

risankizumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#克罗恩病# #ustekinumab# #risankizumab#

NEJM：Risankizumab与Ustekinumab治疗中重度克罗恩病疗效和安全性对比

2025-05-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#炎症性肠病# #ozanimod# #risankizumab# #Mirikizumab# #Brazikumab#

J Gastroenterol：炎症性肠病治疗新篇章——S1P调节剂与IL-23抑制剂

2024-08-01发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#risankizumab# #活动性溃疡性结肠炎# #ECCO 2024#

ECCO 2024：Risankizumab在中度至重度活动性溃疡性结肠炎患者中的疗效和安全性

2024-02-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#克罗恩病# #risankizumab#

IBD：Risankizumab治疗中至重度多重难治性克罗恩病患者的真实世界有效性和安全性

2024-01-23发表于上海

病毒猎手 (审核中...)

前往app查看评论内容

#risankizumab#

Lancet：risankizumab对中重度斑块状银屑病的疗效和安全性

2021-09-03

病毒猎手 (审核中...)

前往app查看评论内容

#risankizumab#

ICER：Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处

2021-09-03

病毒猎手 (审核中...)

前往app查看评论内容

#risankizumab#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2021-09-03

病毒猎手 (审核中...)

前往app查看评论内容

#risankizumab#

NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病

2021-09-03

病毒猎手 (审核中...)

前往app查看评论内容

#risankizumab#

Lancet：Risankizumab治疗中重度银屑病患者的疗效优于阿达木单抗

2021-09-03

病毒猎手 (审核中...)

前往app查看评论内容

#risankizumab##银屑病#

JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响

2021-09-03

科室
- - 订阅+
  - 更多科室
工具
服务